3,7,12-trihydroxycholestan-26-oic acid profile

3,7,12-trihydroxycholestan-26-oic acid: RN given refers to (3alpha,5beta,7alpha,12alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid : A steroid acid that is 5beta-cholestan-26-oic acid which is substituted by hydroxy groups as the 3alpha, 7alpha, and 12alpha positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	122312
CHEBI ID	18402
SCHEMBL ID	2508967
MeSH ID	M0077699

Synonym
coprocholic acid
CHEBI:18402
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid
3,7,12-trihydroxycholestan-26-oic acid
(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholestan-26-oic acid
LMST04030001
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoate
547-98-8
trihydroxycholestanoic acid
(6r)-2-methyl-6-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]heptanoic acid
26-thca
3alpha,7alpha,12alpha-trihydroxy-5-beta-cholestan-26-oic acid
SCHEMBL2508967
cholestan-26-oic acid, 3,7,12-trihydroxy-, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-
3.alpha.,7.alpha.,12.alpha.-trihydroxy-5.beta.-cholestanoic acid
3,7,12-trihydroxycholestan-26-oic acid #
3.alpha.,7.alpha.,12.alpha.-trihydroxycoprostanic acid
5.beta.-cholestan-26-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-
3a,7a,12a-trihydroxycoprostanate
5b-cholestane-3a,7a,12a-triol-26-oate
3a,7a,12a-trihydroxycoprostanic acid
coprocholate
3a,7a,12a-trihydroxy-(6ci,7ci,8ci)5b-cholestan-26-oic acid
3a,7a,12a-trihydroxy-(6ci,7ci,8ci)5b-cholestan-26-oate
3a,7a,12a-trihydroxy-5b-cholestan-26-oate
5b-cholestane-3a,7a,12a-triol-26-oic acid
3a,7a,12a-trihydroxy-5b-cholestan-26-oic acid
DTXSID80862168
(3a,5b,7a,12a)-3,7,12-trihydroxy-cholestan-26-oic acid
Q27103052
3,7,12-trihydroxycoprostanoic acid
HY-113335
CS-0059632
AKOS040755973

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
hydroxy monocarboxylic acid	Any monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
3alpha-hydroxy steroid	A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
7alpha-hydroxy steroid	A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration.
12alpha-hydroxy steroid
steroid acid	Any steroid substituted by at least one carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Metabolism of lipids	500	463
Metabolism of steroids	111	135
Bile acid and bile salt metabolism	31	71
Synthesis of bile acids and bile salts	20	68
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol	16	44
Bile Acid Biosynthesis	17	61
Congenital Bile Acid Synthesis Defect Type II	17	61
Congenital Bile Acid Synthesis Defect Type III	17	61
Familial Hypercholanemia (FHCA)	17	61
Zellweger Syndrome	17	61
Cerebrotendinous Xanthomatosis (CTX)	17	61
27-Hydroxylase Deficiency	17	61
Disorders of bile acid synthesis and biliary transport	18	40

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	11 (35.48)	18.7374
1990's	14 (45.16)	18.2507
2000's	6 (19.35)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	4 (12.90%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (87.10%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pipecolic acid pipecolic acid: RN given refers to cpd without isomeric designation. pipecolic acid : A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2.. pipecolate : A piperidinecarboxylate that is the conjugate base of pipecolic acid.	1.96	1	piperidinemonocarboxylic acid
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.38	2	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	1.97	1	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofibric acid Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.	1.98	1	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
disulfiram [no description available]	1.97	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	1.99	1	amino sulfonic acid; bile acid taurine conjugate	human metabolite
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	3.22	6	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2	1	dihydrogen
phytanic acid Phytanic Acid: A 20-carbon branched chain fatty acid. In phytanic acid storage disease (REFSUM DISEASE) this lipid may comprise as much as 30% of the total fatty acids of the plasma. This is due to a phytanic acid alpha-hydroxylase deficiency.. phytanic acid : A branched-chain saturated fatty acid consisting of hexadecanoic acid carrying methyl substituents at positions 3, 7, 11 and 15.	2.4	2	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid
coenzyme a [no description available]	2.37	2	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
2-methylhexadecanoic acid 2-methylhexadecanoic acid: see also cpd with unspecified methyl position: 112-39-0. 2-methylhexadecanoic acid : A methyl-branched fatty acid that is hexadecanoic (palmitic) acid bearing a methyl substituent at position 2.	2.41	2	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid
pristanic acid pristanic acid : A branched, long-chain saturated fatty acid composed of pentadecanoic acid having methyl substituents at the 2-, 6-, 10- and 14-positions.	2.39	2	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid	human metabolite
3-methylheptadecanoic acid 3-methylheptadecanoic acid: myocardial metabolic tracer tagged with C-11; RN given refers to unlabeled cpd	1.98	1
cholestane-3,7,12,26-tetrol cholestane-3,7,12,26-tetrol: precursor of cholic acid biosyn in man; RN given refers to (3alpha,5beta,7alpha,12alpha)-isomer	1.97	1	12alpha-hydroxy steroid; 26-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid	human metabolite; mouse metabolite
cholic acid Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.	3.36	7	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
3,7-dihydroxycholestan-26-oic acid [no description available]	3.99	14
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	1.97	1	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
palmitoyl coenzyme a Palmitoyl Coenzyme A: A fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.. palmitoyl-CoA : A long-chain fatty acyl-CoA resulting from the formal condensation of the carboxy group of hexadecanoic acid with the thiol group of coenzyme A.	1.97	1	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite
3,7,12,24-tetrahydroxycholestanoic acid [no description available]	2.89	4	12alpha-hydroxy steroid; 24-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; hydroxy monocarboxylic acid	bile acid metabolite
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	1.97	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
3,7,12-trihydroxycholest-24-enoic acid 3,7,12-trihydroxycholest-24-enoic acid: structure given in first source	2.38	2	bile acid
methyl cholate methyl cholate: RN given refers to (3 alpha,5 beta,7 alpha,12 alpha)-isomer	1.98	1	bile acid
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.37	2	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies
Liver Dysfunction [description not available]	2.01	1
Inborn Errors of Metabolism [description not available]	2.67	3
Liver Diseases Pathological processes of the LIVER.	2.01	1
Metabolism, Inborn Errors Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.	2.67	3
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	2.02	1
Dysarthosis [description not available]	2.02	1
Deficiency, Mental [description not available]	2.02	1
Decreased Muscle Tone [description not available]	2.39	2
Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)	2.02	1
Cancer of Liver [description not available]	2.38	2
Experimental Hepatoma [description not available]	1.98	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.38	2
Hepatoblastoma A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)	1.98	1
Adrenoleukodystrophy, Autosomal Neonatal Form [description not available]	2.69	3
Peroxisomal Disorders A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.	2.69	3
Bile Duct Obstruction, Intrahepatic [description not available]	2	1
Cerebro-Hepato-Renal Syndrome [description not available]	2.39	2
Cholestasis, Intrahepatic Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).	2	1
Zellweger Syndrome An autosomal recessive disorder due to defects in PEROXISOME biogenesis which involves more than 13 genes encoding peroxin proteins of the peroxisomal membrane and matrix. Zellweger syndrome is typically seen in the neonatal period with features such as dysmorphic skull; MUSCLE HYPOTONIA; SENSORINEURAL HEARING LOSS; visual compromise; SEIZURES; progressive degeneration of the KIDNEYS and the LIVER. Zellweger-like syndrome refers to phenotypes resembling the neonatal Zellweger syndrome but seen in children or adults with apparently intact peroxisome biogenesis.	2.39	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.97	1
Diseases in Twins Disorders affecting TWINS, one or both, at any age.	1.97	1
Abnormalities, Multiple Congenital abnormalities that affect more than one organ or body structure.	1.97	1
Adult Refsum Disease [description not available]	1.96	1
Hepatocellular Carcinoma [description not available]	1.96	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1.96	1
Symptom Cluster [description not available]	1.96	1
Syndrome A characteristic symptom complex.	1.96	1

3,7,12-trihydroxycholestan-26-oic acid

Description

Cross-References

Synonyms (35)

Roles (1)

Drug Classes (5)

Pathways (14)

Research

Studies (31)

Market Indicators

Research Demand Index: 10.83

Study Types